Trial
NCT00323063
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Rutgers, The State University of New Jersey
Collaborators
National Cancer Institute (NCI); Novartis Pharmaceuticals; Rutgers Cancer Institute of New Jersey
Condition
Breast Cancer
Intervention
gemcitabine hydrochloride
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-03-29